Oruka Therapeutics Inc
NASDAQ:ORKA
Oruka Therapeutics Inc
NASDAQ:ORKA
Price:
43.81
USD
9.8%
Market Cap:
$2.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
US |
|
Armadale Capital PLC
LSE:ACP
|
UK |
|
P
|
PJBumi Bhd
KLSE:PJBUMI
|
MY |
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
US |
|
M
|
Medco Energi Internasional Tbk PT
IDX:MEDC
|
ID |
|
XPS Pensions Group PLC
LSE:XPS
|
UK |
|
Z
|
Zenas Biopharma Inc
NASDAQ:ZBIO
|
US |
|
Goldoz Ltd
ASX:G79
|
AU |
|
Hitachi Metals Ltd
TSE:5486
|
JP |
|
O
|
Optimi Health Corp
CNSX:OPTI
|
CA |
|
Longfor Group Holdings Ltd
HKEX:960
|
CN |
|
T
|
Texas Community Bancshares Inc
NASDAQ:TCBS
|
US |
|
Shan Dong Lubei Chemical Co Ltd
SSE:600727
|
CN |
|
Global Payments Inc
NYSE:GPN
|
US |
|
W
|
Warisan TC Holdings Bhd
KLSE:WARISAN
|
MY |
|
M
|
Mincon Group PLC
ISEQ:MIO
|
IE |
|
S
|
Soosan INT Co Ltd
KOSDAQ:050960
|
KR |
|
adesso SE
OTC:ADSGF
|
DE |
|
F
|
Function International PCL
SET:FTI
|
TH |
|
Senzime AB (publ)
STO:SEZI
|
SE |
|
M
|
MMAG Holdings Bhd
KLSE:MMAG
|
MY |
|
G
|
GTI Holdings Ltd
HKEX:3344
|
HK |
|
Berkeley Group Holdings PLC
LSE:BKG
|
UK |
Multiples-Based Value
There is not enough data to reliably calculate the multiples-based value of ORKA.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ORKA
Multiples-Based Value
Base Case
Not Available
Multiples Across Competitors
ORKA Competitors Multiples
Oruka Therapeutics Inc Competitors
Oruka Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Oruka Therapeutics Inc
NASDAQ:ORKA
|
2.1B USD | 0 | -20.2 | -14.7 | -14.7 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 88 | 14.6 | 20.3 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 6.2 | -96.2 | 951.3 | -107.4 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.6 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.6B USD | 5.8 | 20.1 | 12.6 | 15.5 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.6B USD | 9.6 | 29.2 | 21.9 | 22.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.2B USD | 5.6 | 17.8 | 13.2 | 15.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.2 | 35.2 | 11.6 | 14.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
